2025 Call for Abstracts
Submission portal opened May 1
The Call for Abstracts for the 2025 San Antonio Breast Cancer Symposium® opened at 8 a.m. Central Time on Thursday, May 1, 2025, and will remain open until 6 p.m. CT on July 9, 2025.
Late-Breaking Abstracts will be accepted from September 2 through September 30, 2025, at 11:59 PM CT.
Please note:
- Financial disclosures will be required upon acceptance.
- Upon acceptance, the presenting author will receive presentation guidelines, submission links and a detailed timeline of deadlines.
For answers to frequently asked questions, read our Abstract Guidelines (PDF)
Scholar Awards
Every year, the San Antonio Breast Cancer Symposium® and its partners offer scholarships to help offset the cost of coming to the symposium for some presenters. The Call for Abstracts for the 2025 opened at 8 a.m. Central Time on Thursday, May 1, 2025, and will remain open until 6 p.m. CT on July 9, 2025.
The purpose of scholar awards is to promote the education and professional development of early-career clinicians and scientists who are actively pursuing research in breast cancer by encouraging and facilitating their attendance at the 2025 San Antonio Breast Cancer Symposium.
SABCS 2024 proceedings
The full proceedings of SABCS 2024 will be published in Clinical Cancer Research, available from the American Association for Cancer Research during the second quarter of 2025. We will publish more details about the publication as they become available.
Confirmation of No Prior Publication/Presentation
Authors who submit an abstract confirm they have not previously published these data, they have not previously presented them at another scientific meeting, and that they are not planning to present or publish them prior to the dates of the SABCS® 2025. Preprints (draft research papers posted online before peer review) are not considered to be a prior publication if they are posted online before abstracts are submitted SABCS®.
Abstracts submitted to SABCS® are confidential and embargoed until SABCS® publishes the abstracts.
Certain laws may require disclosure of clinical trial data through federal and international registries within a specific amount of time following trial completion, or disclosure of clinical trial data by federal and international agencies for regulatory purposes related to drug safety and efficacy. Such disclosures will not be considered a violation of the SABCS’s Embargo Policy, but the courtesy of advance notice to the SABCS® by email at sabcs@uthscsa.edu is requested.
Any other exceptions to this policy are at the discretion of SABCS® leadership.